RxDoctor Payments Data

Linda Cadaret, MD

Advanced Heart Failure and Transplant Cardiology · Iowa City, IANPI 1437121407

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,006 of the $13,652 with a category attached, or 66.0%. 11 manufacturers reported payments, led by United Therapeutics Corporation at 49.1% of the total. Reporting peaked in 2019 at $4,608 and has fallen 98.4% since, to $76 in 2025.

$13,652in general payments, 2019–2025

Across 55 payments — averaging $248.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$7K
  • Janssen Research & Development, LLC$5K
  • Merck$1K
  • Actelion Pharmaceuticals, Ltd$862
  • Abbott$278
  • Endotronix, Inc.$94
  • plus $166 from 5 others
$5,123,549in research payments, 2019–2025

Across 293 payments — averaging $17,487 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$3.3M
  • Janssen Research & Development, LLC$928K
  • Endotronix, Inc.$405K
  • United Therapeutics Corporation$236K
  • Actelion Pharmaceuticals, Ltd$164K
  • Bayer$44K
  • plus $71K from 5 others

What the payments were for

  • Consulting fees$9,00666%
  • Travel & lodging$3,14323%
  • Food & beverage$1,50311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$38,238
Medicare patients
174
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan291$3,693,284
Tyvaso DpiTreprostinil133$3,126,584
UptraviSelexipag137$3,040,958
WinrevairSotatercept-Csrk94$1,564,258
AdempasRiociguat95$1,265,745
Orenitram ErTreprostinil Diolamine62$1,175,334
VyndamaxTafamidis32$692,800
Ambrisentan112$270,647
TracleerBosentan11$138,103
EntrestoSacubitril/Valsartan114$132,850
Tadalafil146$121,575
JardianceEmpagliflozin74$72,714
Sildenafil Citrate235$55,638
FarxigaDapagliflozin Propanediol43$35,158
EliquisApixaban23$26,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckWinrevair$1,044$1,564,25894 claims
BayerAdempas$48$1,265,74595 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →